Climb Bio Reports Positive Phase 1b Data for Budoprutug in ITP

summarizeSummary

Climb Bio reported positive Phase 1b clinical trial results for its lead drug candidate, budoprutug, in patients with primary immune thrombocytopenia (ITP), showing good safety and promising efficacy.

check_boxKey Events · Product Development and Regulatory · CLYM

• Positive Phase 1b Clinical Data

  Climb Bio announced initial positive data from the Phase 1b portion of its study evaluating intravenous budoprutug in adults with primary ITP.

• Favorable Safety Profile

  Budoprutug was generally well tolerated at 250 mg and 500 mg doses, with no serious adverse events or treatment discontinuations.

• Encouraging Efficacy Signals

  In the 250 mg cohort, patients showed over 90% B-cell depletion, a mean platelet count increase of 111,000 platelets/µL, and durable platelet responses in 4 out of 6 patients, including those previously treated with rituximab.

• Continued Clinical Development

  The results support ongoing clinical evaluation of budoprutug in ITP, with enrollment continuing in the 1000 mg cohort and additional data expected by year-end 2026.

auto_awesomeAnalysis · CLYM · Life Sciences

Climb Bio announced encouraging Phase 1b clinical data for its lead asset, budoprutug, in primary immune thrombocytopenia (ITP). The drug demonstrated a favorable safety profile and promising efficacy signals, including durable platelet responses and activity in heavily pretreated patients, some of whom had failed prior rituximab therapy. This positive data significantly de-risks the intravenous formulation of budoprutug and supports its continued development, building on the company's recent positive news flow and strong cash position.